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STUDY PROTOCOL Open Access
Frailty Intervention Trial iN End-Stage
patientS on haemodialysis (FITNESS): study
protocol for a randomised controlled trial
Benjamin M. Anderson1,4 , Mary Dutton1, Edward Day2, Thomas A. Jackson3,4, Charles J. Ferro1 and Adnan Sharif1,5*
Abstract
Background: Frailty is a state of low physiological reserve and multi-systemic dysregulation that leads to susceptibility
to external stressors; it is associated with adverse outcomes. North American data suggest that haemodialysis recipients
are more likely to be frail than the general population, although data on UK cohorts are lacking. Furthermore, with a
multitude of assessment tools, it is difficult for the clinician to ascertain which is most suitable for this population. The
FITNESS Study aims to measure the prevalence and outcomes associated with frailty in a large UK haemodialysis cohort
to determine the optimum frailty tool as defined by predictive value for mortality/hospitalisation and to conduct a
feasibility study exploring a multi-disciplinary clinical intervention to improve frailty among haemodialysis recipients.
Methods/design: The study will follow a cohort multiple randomised controlled trial design; the initial cohort study
will identify participants to be invited into a subsequent open-label randomised controlled trial. Eligible patients will be
identified and recruited from their usual haemodialysis session. They will be invited to complete tasks and
questionnaires collecting data on sarcopenia, immunosenescence, mood, cognition, disability, and comorbidity. Fifty
pre-frail participants with suitable English proficiency will be randomly selected from this cohort to participate in the
randomised controlled trial phase of the study. Further stratified randomisation will occur to assign these 50 participants to
active or passive groups. The active group will receive a psychologically supported, patient-centred, multi-disciplinary
intervention into frailty, in what we believe to be a first within this patient group. The control group will receive usual
haemodialysis standard of care. All participants will be followed up using electronic patient records for outcomes to include
hospitalisation and mortality. Primary outcomes for this phase of the study will be feasibility and tolerability of the clinical
intervention study.
Discussion: The study will collect data on multiple aspects of frailty allowing for a rich dataset for detailed analysis. We
believe this will be the first study to explore a psychologically supported, patient-centred intervention in this patient group.
Trial registration: Clinicaltrials.gov, NCT03071107. Registered on 6 March 2017.
Background
Frailty is a state of low physiological reserve and multi-
systemic dysregulation that leaves the individual suscep-
tible to external stressors [1]. Sarcopenia, an age-related,
involuntary loss of skeletal muscle mass and strength
and/or function is often seen as part of the frailty syn-
drome [2, 3]. Immunosenescence is another component
of frailty, characterised by age-related deterioration in
immune function, and is thought to be modifiable
through exercise [4]. Frailty is prevalent among patients
receiving haemodialysis, ranging between 30% to as high
as 78% dependent upon the diagnostic tool used, and is
associated with significant adverse outcomes such as
falls, hospitalisation, mortality, and loss of functional in-
dependence [5–17]. These studies were conducted in
North American cohorts, primarily using the Fried
Frailty Phenotype, and to date we have no information
regarding the prevalence or outcomes associated with
frailty in a UK cohort. Dialysis outcomes differ
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significantly between these populations [18], limiting the
generalisability of US data to UK cohorts. Whilst there
are a range of validated subjective and objective mea-
surements for frailty, it is unclear which has the most
utility to guide clinical practice.
While frailty is not a fixed physiological state, there is
currently no evidence to support any intervention tar-
geted to improve frailty within patients receiving haemo-
dialysis. In the general elderly population, there is some
evidence of the utility of a multi-disciplinary approach
to intervene on frailty. For example, the FIT study uti-
lised a multi-factorial inter-disciplinary intervention
which reduced frailty among older people by 14.7% at 12
months [19]; however, there were no other outcomes
measured, such as quality of life, mortality, or hospital
admissions. The majority of frailty intervention studies
performed in both general and dialysis populations do
not use validated measures of frailty for either inclusion
criteria or outcome measures, but show that functional
outcomes (i.e. disability) can be improved with exercise
[20–22]. For those patients proceeding to kidney trans-
plantation, frailty at the time of transplantation has been
associated with poorer post-transplant outcomes [23–
26], although there have not been any published at-
tempts at “prehab” in prospective transplant recipients.
Therefore, whether such a strategy would lead to more
haemodialysis patients being deemed suitable to benefit
from transplantation remains to be seen.
We speculate that patient behaviours can be modified to
impact upon frailty. To the best of our knowledge, there
have not been any published attempts to intervene upon
frailty using behavioural change. Meta-analysis and
meta-regression have shown that behavioural change tech-
niques (BCTs) congruent with control theory [27] are sig-
nificantly more effective than those that are not [28–30].
These include node-link mapping (NLM), which incorpo-
rates visual representations of behavioural change, along-
side potential aids and barriers to this change with
strategies to overcome these [31]. NLM is a technique
already successfully used in addiction psychiatry [32].
Social behaviour and network therapy (SBNT) seeks to
identify the level of social support for an individual, and
aims to include significant supportive others in setting
and monitoring goals, and has been successfully used in
alcohol abstinence after liver transplantation [33].
It is speculated that long-term changes in behaviour
and activity are likely to be required to impact upon
frailty and, as such, BCTs may have a role to play in
frailty interventions.
Aims
This study aims to: 1) measure prevalence and outcomes
associated with frailty in a large UK haemodialysis co-
hort; 2) determine the optimum frailty assessment tool
for UK patients receiving haemodialysis, as defined by
predictive value for mortality/hospitalisation; and 3) con-
duct a feasibility study exploring a multi-disciplinary
clinical intervention to improve frailty status among pa-
tients receiving haemodialysis
Methods/design
This is a prospective, single centre, open-label, cohort
multiple randomised controlled trial (cm-RCT) [34] which
will be split into two elements. Work package 1 is a cohort
study of prevalent haemodialysis patients which aims to
identify the prevalence of frailty among this population
and outcomes associated with frailty such as mortality,
hospitalisation, and quality of life. Patients from work
package 1 who are identified as “pre-frail”, as defined by
the Frailty Index, will then be invited to participate in
work package 2 which will compare the effect of active
lifestyle intervention versus current standard of care upon
frailty measurements and outcomes. All haemodialysis pa-
tients who meet the inclusion/exclusion criteria will be in-
vited to participate in work package 1. As part of the
cm-RCT design, eligible patients will be selected for invi-
tation to participate in work package 2 according to a
stratified randomisation module. Invited participants will
be randomised into active or passive intervention groups.
The duration of the clinical intervention in work package
2 will be 6 months, with electronic data-linkage follow-up
for 5 years after study participation to allow for continued
capture of outcome measures.
Study setting
Patients will be recruited from a single nephrology
centre located in Birmingham, UK. The centre consists
of one in-hospital dialysis unit and 10 private-provider
satellite units distributed around the region, and pro-
vides haemodialysis to 1000 patients. It is planned to re-
cruit at least 602 patients from this population to work
package 1 with 50 patients recruited to work package 2.
Birmingham and the West Midlands is a diverse,
multi-cultural population and, as such, we will aim to re-
cruit proportionate numbers of black, Asian and minor-
ity ethnic (BAME) participants to the study to accurately
represent the community our hospital serves.
Inclusion and exclusion criteria
Work package 1: inclusion criteria
The inclusion criteria for work package 1 are: 1) aged 18
years and over; 2) received regular haemodialysis of at least
3 months duration; and 3) able to provide informed consent.
Work package 1: exclusion criteria
The work package 1 exclusion criterion is having
received inpatient care within 4 weeks of recruitment
(unless for vascular access).
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Work package 2: inclusion criteria
The inclusion criteria for work package 2 are: 1) aged 18
years and over; 2) received regular haemodialysis of at
least 3 months duration; 3) able to provide informed con-
sent; 4) a participant in work package 1; 5) identified as
pre-frail in work package 1; and 6) suitable English profi-
ciency, i.e. an ability to understand a medical consultation
in English.
Work package 2: exclusion criteria
The exclusion criteria for work package 2 are: 1) deemed
unsuitable to complete study (clinician advice); 2) cur-
rently enrolled in another clinical intervention trial; 3)
receiving emergency inpatient care within 4 weeks of re-
cruitment/assessment (patients admitted for routine
procedures, e.g. dialysis access, will be eligible for inclu-
sion); and 4) planned live donor kidney transplant dur-
ing study period.
Work package 1
Study protocol
Potential participants will be identified through a review
of all patients attending haemodialysis sessions, currently
available from electronic patient records (EPRs) and from
clinicians in charge of each haemodialysis unit. Patient in-
formation leaflets (PILs) will be given to the patients in
advance of a discussion with the researcher either by post
or in person. Individuals will be approached at their usual
dialysis unit appointment for discussion and potential re-
cruitment to the study. Potential participants will be given
the opportunity to reflect on the information given both
verbally and within the PIL. No fixed time is specified for
the length or timing of this prior interview as it will be
dependent upon the patient’s understanding of their
underlying disease and of the research project. It is im-
portant that non-English speaking patients are given full
opportunity to be informed and recruited to the study, to
accurately reflect the demographics of the haemodialysis
population. In these instances, we will use any possibility
to discuss the study with patients to aid participation and
consent. This may include using family, friends, dialysis
staff, or the investigator team who may be proficient in
the patients preferred language (e.g. Urdu, Punjabi).
Written consent will be received from each patient enter-
ing the study.
Baseline assessment
Prior to the patient being connected to the dialysis ma-
chine, the following assessments will take place: 1) timed
walk over 4 m; 2) assessment of grip strength with a dyna-
mometer; and 3) Montreal Cognitive Assessment (MoCA)
When the patient is dialysing, the following assess-
ments will be performed: 1) quadriceps ultrasound as-
sessment; 2) questionnaires will be given to participants
in either paper or electronic format via a tablet device, ac-
cording to patient preference, including the 3-level version
of the EuroQol five dimensions (EQ-5D-3 L) and the
Patient Health Questionnaire (PHQ)-9 (where a PHQ-9
score of 20 or over may indicate depression and a discus-
sion will be held with the patient asking whether they
would like a discussion with their nephrologist or a refer-
ral to the renal psychology service); and 3) a questionnaire
related to each frailty instrument, demographic data, and
social history (level of education, employment status, na-
ture of employment, smoking, and alcohol history).
EPRs will be interrogated for data on comorbidities, dia-
lysis parameters, previous transplantation, biochemical
data, medication history, and social deprivation score.
The patient’s nephrologist will be invited to complete
a Clinical Frail Scale for individual participants within 1
month of the baseline clinical assessment.
Data handling
Data collected throughout the study will be entered onto
a study-specific database REDCap™ (Research Electronic
Data Capture) [35] with secure storage and full oversight
from information governance. Any paper records which
form part of the source data for the study will be
retained securely at site.
Patients will be consented for electronic data capture
of clinical parameters (e.g. biochemical data) from
University Hospitals Birmingham EPR at 1 month, 3
months, 1 year, 3 years, and 5 years post-recruitment (fa-
cilitated through informatics linkage utilising Hospital
Patient Registration number). In addition, clinical out-
comes (e.g. hospital admissions, medical events, surgical
procedures, death, etc.) will be electronically captured
from Hospital Episodes Statistics for the same time
points (facilitated through informatics data linkage utilis-
ing National Health Service (NHS) numbers). This will
allow long-term data capture of important clinical out-
comes without direct patient involvement.
Work package 2: plan of investigation
Study protocol
The FITNESS protocol has been designed and reported in
line with SPIRIT guidelines, with an attached SPIRIT flow
diagram (see Fig. 2 later) and checklist (Additional file 1) [36].
Recruitment and consent
Potential participants will be identified through their
previous participation in work package 1. Patients scored
as “pre-frail” will randomly be selected to participate in
work package 2. Patient information sheets will be given
to the patients in advance of a discussion with the re-
searcher either by post or in person. Individuals will be
approached at their usual dialysis unit appointment for
discussion and potential recruitment to the study.
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Potential participants will be given the opportunity to
reflect on the information given both verbally and within
the written information sheet. No fixed time is specified
for the length or timing of this prior interview as it will
be dependent upon the patient’s understanding of their
underlying disease and of the research project. A certain
level of English proficiency will be necessary to partici-
pate in the intervention, however it is important that
non-native English speaking patients are given full op-
portunity to participate in this study and the same
methods will be used as in work package 1 to facilitate
this. Written consent will be received from each patient
entering the study. A study patient identifier will be allo-
cated and recorded on the study recruitment log.
Work package 1 patients who meet eligibility criteria will
be randomly selected for participation in work package 2
using REDCap™ (in random permuted blocks within strata
to balance numbers and characteristics). Participants who
have subsequently been approached and given consent to
participate in work package 2 will be randomised once
more using REDCap™ (in random permuted blocks within
strata to balance numbers and characteristics) into one of
the following lifestyle intervention groups (n = 25 for each
intervention group for a total of 50 participants). As part
of the cm-RCT design, data from pre-frail work package 1
patients who were eligible but not selected for participation
in work package 2 will provide a further comparator group
for analysis. As an open-label study, neither participants
nor researchers will be blinded to group allocation.
Active intervention group
This group will receive interventions designed to address
frailty and will consist of dietitian referral for dietetic ad-
vice and physiotherapist referral for a graded exercise
programme. The participants will receive this in addition
to their usual haemodialysis standard of care. To reduce
potential bias, neither the physiotherapist nor the
dietitian will have regular input with haemodialysis
patients as part of their job plan. Each patient will have
five face-to-face appointments with the dietitian and
physiotherapist (lasting 45–60 min) at baseline, week 6,
week 12, week 18, and week 24. Brief telephone reviews
will be conducted between appointments (approxi-
mately2–3 weeks after each face-to-face appointment) to
review progress and provide additional support during
the active intervention period. Some appointments may
be substituted with telephone support if preferred by the
patient. Patients will have their diet reviewed by a
dietitian and healthy eating advice will be given based
upon guidelines issued by the British Dietetic Associ-
ation [37], which provide recommendations for mini-
mum protein intake in dialysis patients. Patients will be
advised to keep food and exercise diaries to monitor
compliance with initiated changes and will be followed
up by the research team prospectively (using face-to-face
appointments and telephone reviews) to monitor progress
and reinforce the advice (in addition to routine clinic visits).
In addition, a graded exercise programme will be estab-
lished by the physiotherapist to increase physical activity in
line with both the patient’s stated goals at initial assessment
and their deficits identified upon frailty scoring.
The dietitian and physiotherapist will be supported by a
Senior Lecturer and Consultant in Addiction Psychiatry
who has expertise in behavioural change therapy. The
dietitian and physiotherapist will be trained with motiv-
ational interviewing skills and the following psychological
tools will be utilised to support the active intervention.
Cognitive behavioural therapy (CBT) intervention in-
corporating NLM is simple to train and apply. We will
utilise simple goal-setting techniques, combined with re-
lapse prevention strategies, and a simple visual representa-
tion system for presenting CBT-type interventions. NLM
is more effective than standard consultations for improv-
ing the therapeutic alliance, increasing focus on key issues
during the session, and improving outcomes. There is also
evidence of efficacy in patients with poor reading skills or
working in a language other than their first language
(important for our patient demographics) [31].
SBNT is an intervention that draws in members of the
family, social network, and mutual self-help or peer sup-
port groups to help the patient set and achieve goals. It
has been developed and tested by colleagues in Birming-
ham, with an evidence base in the context of liver trans-
plantation [33]. A combination of these two techniques,
together with motivational interviewing [38] by the
dietitian and physiotherapist after appropriate training,
will facilitate supportive psychosocial interventions to
change lifestyle behaviour.
Passive control group
This group will receive their usual standard of care from
their treating dialysis centre, including usual dietitian in-
put. However, there will be no psychosocial intervention
or focused exercise and dietary monitoring programme.
Follow-up will be at routine clinic visits only, where life-
style modification advice will be reinforced as per usual
clinical practise. Physiotherapy may be offered to these pa-
tients as per standard referral guidelines but will not have
the psychosocial underpinning of the intervention group.
Both groups will undergo a repeat frailty testing during
the mid-point (3 months ± 2 weeks) and the end of study
intervention (6 months ± 2 weeks) (see Figs. 1 and 2). The
aim is to assess if there is any change in frailty status which
will provide data to underpin a power calculation for a sub-
sequent large-scale study. Additional pre-specified sec-
ondary outcomes will be collected as highlighted below
in the protocol. Participants will also be invited to
complete a series of questionnaires to ascertain the
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Work 
Package 
1: All 
eligible 
participants
Non-Frail
Frail
Pre-Frail Not Invited to
Work Package 2
Invited to Work 
Package 2 
(n=50)
Passive (n=25): Normal
haemodialysis standard of care
Active (n=25): Dietician and 
physiotherapist input
Randomisation Bio-clinical phenotype assessments X 3
Eligibility and Randomisation
Bio-clinical phenotype assessment
Eligible for
Work Package 2 
Not Eligible for
Work Package 2
Work Package 2: 6-monthsWork Package 1
5-year 
electronic 
follow up of 
all Work 
Package 1 
and 2 
participants 
for 
outcomes
Fig. 1 Flowchart of participants in FITNESS work packages 1 and 2. As part of the cm-RCT methodology, all eligible participants will first be randomised for
potential invitation to the study (n = 50). Potential recruits will then be approached for involvement in work package 2 and, after further valid consent, will
then be randomised into active or passive groups
Fig. 2 Spirit figure for work package 2
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tolerability and suitability of the intervention trial, and
to guide the delivery of the trial on a larger scale.
Study outcomes
Primary endpoint
The primary endpoint is the feasibility and tolerability of
the clinical intervention study (recruitment rates, loss to
follow-up, and study withdrawal).
Secondary endpoints
Secondary endpoints include: 1) refinement of the
multi-disciplinary intervention based upon views from par-
ticipants and stakeholders (from post-study questionnaires);
2) change in frailty status (based on Fried Frailty Phenotype,
Clinical Frailty Scale); 3) difference in clinical and biochem-
ical outcomes; 4) quality of life score (EQ-5D-3 L); 5) re-
ceipt of kidney transplant; 6) vascular access failure; and 7)
long-term clinical outcomes (death, cardiac events, hospi-
talisation) to University Hospital Birmingham electronic pa-
tient records and Hospital Episode Statistics
Data collection
Tissue collection
Blood samples will be taken from the 50 work package 2
participants, alongside 50 work package 1 participants
each from the frail and non-frail groups. Plasma, serum,
peripheral blood mononuclear cells (PBMCs) and whole
blood will be stored for future immunophenotyping.
Electronic data capture
Electronic data capture will continue in work package 2
as previously described in work package 1.
Data monitoring and risk
There are no specific risks anticipated with this study.
However, any study-related adverse events (AEs) will be
documented and reported to the steering committee.
Should a participant report any thoughts of deliberate
self-harm or suicide, or complete a PHQ-9 score of over
20 during the study, a discussion will be held with the
patient asking whether they would like a referral to the
patient’s nephrologist or psychology services at the trust.
A serious adverse event (SAE) is defined by the Health
Research Authority as an untoward occurrence that: 1)
results in death; 2) is life-threatening; 3) requires hospital-
isation or prolongation of existing hospitalisation; 4)
results in persistent or significant disability or incapacity;
5) consists of a congenital abnormality or birth defect; and
6) is otherwise considered medically significant by the
investigator.
An SAE occurring to a research participant will be re-
ported to the Research Ethics Committee (REC) where
in the opinion of the Chief Investigator the event was: 1)
related (it resulted from the administration of any of the
research procedures); and unexpected (the type of event
is not listed in the protocol as an expected occurrence).
Any SAE will be reported to the REC within 15 days
of the Chief Investigator becoming aware of the event.
All other SAEs will need reporting as AEs on the case
report form.
Exceptions to expedited reporting include hospitalisa-
tion for: 1) treatment which was elective or pre-planned,
or for a pre-existing condition not associated with any de-
terioration in condition, e.g. pre-planned hip replacement
operation which does not lead to further complications;
and 2) treatment on an emergency, outpatient basis for an
event not fulfilling any of the definitions of serious as
given above and not resulting in hospital admission.
Patients will be asked if any adverse events have oc-
curred when they attend for any trial-related procedure.
Participant withdrawal
In the event of patients wishing to discontinue in the trial,
the participant would be withdrawn from the study with
the assurance that their usual care will continue unaffected.
Identifiable data or tissue already collected with consent
would be retained and used in the study. No further data or
tissue would be collected, or any other research procedures
carried out on or in relation to the participant. If the patient
consented to have long-term electronic tracking of their
outcomes, this would be continued.
Statistics
The principle parameters being examined in work pack-
age 1 are hospitalisation, mortality, and their association
with frailty. Based upon US data [6], we have assumed
an adjusted risk ratio of 2.24 for 1-year mortality and
1.56 for 1-year mortality and/or hospitalisation for frail
versus non-frail patients receiving haemodialysis. We
have assumed a baseline (non-frail) risk of 5% for 1-year
mortality and a 40% risk of 1-year mortality/hospitalisa-
tion, powered to 0.8 and with a confidence interval of
0.95. We therefore calculate a sample size of 602 to be
adequately powered to demonstrate a difference in
1-year mortality or 150 patients to be powered for
1-year mortality/hospitalisation.
Work package 2 is designed as a feasibility study so no
specific power calculations have been made. However,
one of the secondary outcomes is to use the data regard-
ing effect sizes to determine the sample required for a
larger multi-centre study based upon the feasibility of
work package 2.
Statistical analysis will be performed using standard soft-
ware (SPSS Version 25, Mac version, Chicago, USA).
Normality of data will be assessed using the Kolmogorov-
Smirnov tests. Paired sample t test and Wilcoxon signed
rank test, for parametric and non-parametric data respect-
ively, will be used to compare the means of two variables
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from a single group. Comparison of data between groups
will be made using unpaired student t tests and the
Mann-Whitney test for parametric and non-parametric
data, respectively. Categorical data will be analysed using
Pearson’s or Spearman’s test as appropriate. A p value <
0.05 is considered significant in the statistical analysis.
Discussion
Frailty has been linked with adverse outcomes in North
American haemodialysis cohorts [5–12, 17, 39, 40], but
these data are not transferrable to UK patients since US
dialysis populations have adverse outcomes compared
with UK populations [18]. There is no agreement over
the best frailty tool to assess patients, both within the
general population and within haemodialysis cohorts.
The Fried Frailty Phenotype [41] and Rockwood Frailty
Index [42] are the most commonly cited instruments in
geriatric and renal-specific literature, with the Clinical
Frailty Scale also featuring in haemodialysis cohorts [12].
The Edmonton Frail Scale is recommended by the Brit-
ish Geriatric Society, but has yet to be validated in pa-
tients receiving haemodialysis [43]. We expect each of
these instruments to show association with negative out-
comes, but it is not yet known which of these provides
the best predictive value in patients receiving haemodi-
alysis. The cohort analysis embedded within this study
will therefore seek to address this by comparing frailty
instruments for their association with negative out-
comes, whilst also addressing renal-specific outcomes
such as transplantation or dialysis access failure. These
data will allow renal practitioners to better understand
which frailty tool is optimal for their population.
Multi-disciplinary intervention into frailty has shown
promise [19], although a systematic review and meta-ana-
lysis was limited by the lack of validated measures of
frailty as inclusion criteria and outcome measures in the
published studies to date [22]. To our knowledge, there
are no published data regarding frailty interventions
within the UK haemodialysis population, although a US
study showed self-reported disability could be reduced by
such an intervention [20].
There is an urgent need for the development of inter-
ventions capable of enacting long-term change within pa-
tient groups. Our experience in Birmingham suggests that
BCTs can modify behaviour with the potential to change
clinical outcomes [33, 44]. Therefore, a patient-centred,
frailty-specific BCT intervention may be beneficial for frail
patients receiving haemodialysis and may improve clinical
and patient-reported outcomes.
Work package 2 is an unblinded, randomised controlled
study using a psychologically supported multi-disciplinary
intervention into frailty compared with a control group
which receives standard care. This will be used as a basis
for exploring whether a large scale, multi-centre trial is
feasible and warranted, while also providing data upon ef-
fect sizes to allow subsequent power calculation for such a
study. We chose the “pre-frail” group as the focus of this
intervention, firstly because they arguably have the most
to gain—not progressing to frailty—and, secondly, because
pre-frailty represents a much less heterogeneous group
than frailty, the latter of which would include essentially
functionally independent individuals with a few accumu-
lated deficits along with bed-bound individuals and those
approaching end-of-life. The pre-frail group therefore
have an easily definable set of characteristics and have the
ability to participate in, and benefit from, the proposed
interventions.
One of the principle strengths of the study design is
the breadth of data being collected. Researchers will col-
lect data on multiple aspects of frailty from consenting
patients to include aspects of sarcopenia (muscle mass,
quality, and function), immunosenescence, functional
status/disability, mood, cognitive status, and medical his-
tory. This rich dataset will allow detailed analysis of the
heterogeneity or otherwise of frailty within the cohort.
As work package 1 is a single time-point analysis with
electronic follow-up thereafter, dropout should be min-
imal and large numbers of patients could be recruited to
allow such detailed analysis to have real meaning to cli-
nicians. Another strength lies in the cm-RCT design,
whereby stratified random sampling will identify trial
participants from consenting eligible cohort study par-
ticipants. This approach has several benefits, including
amelioration of potential attrition bias in the control
group, long-term data follow-up for a large comparator
group, and increased power for the study [34].
A weakness of the study is the single time-point as-
sessment in work package 1, as frailty is known to
change over time [45–47]. Nevertheless, objective frailty
measurements still hold prognostic value [48].
This cohort randomised controlled trial will assess the
prevalence and associations of frailty using validated meas-
urement tools and test the utility of these instruments in
predicting adverse outcomes. The study will also assess the
feasibility of conducting a randomised controlled trial using
an intervention designed to improve frailty.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 121 kb)
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